Not sure what type of response you're after! The risk of...

Not sure what type of response you're after! The risk of clinical failure is similar to that of any other pharma / biotech involved in clinical research.

From a business standpoint though, PXS is in a much stronger position to where it was a number of years ago to overcome any headwinds along the way (inc a very strong cash position, a number of compounds in areas with high unmet medical needs as well as an impressive share register). After all, BVF Partners & Co understand the risk and are happy to take a big position in the company. We all have a similar choice to make...